May 17th, 2021
On May 17th, 2021, HRSA sent six pharmaceutical manufacturers letters stating that their restriction of 340B pricing to Contract Pharmacies is in direct violation of 340B statute.
September 22, 2021
Effective August 1, 2021, Boehringer Ingelheim will only provide 340B priced product to a single Contract Pharmacy. Federal Grantees not subject to limitations.
Effective September 1st, 2021, Merck will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.